Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.

OBJECTIVE To evaluate the efficacy of donepezil in patients with early-stage Alzheimer disease. DESIGN Multicenter, randomized, double-blind, 24-week, placebo-controlled study that enrolled patients with early-stage Alzheimer disease. Patients were randomized in an approximately 2:1 ratio to donepezil, 5 mg/d, for the first 6 weeks, with a forced escalation to 10 mg/d thereafter (n = 96), or placebo (n = 57). The primary efficacy measure was the modified Alzheimer Disease Assessment Scale-cognitive subscale. Secondary efficacy measures included the Mini-Mental State Examination, the Computerized Memory Battery Test, the Clinical Dementia Rating Scale-Sum of the Boxes, the Patient Global Assessment Scale, and the Apathy Scale. RESULTS Improvements favoring donepezil on the Alzheimer Disease Assessment Scale-cognitive subscale were found at weeks 12 and 24 and at the end point (last observation carried forward); treatment differences were 1.9 (P = .03), 2.3 (P = .008), and 2.3 (P = .001) points, respectively. Improvements favoring donepezil on the Mini-Mental State Examination were found at weeks 6, 12, and 24 and at the end point (last observation carried forward); treatment differences were 1.4 (P = .02), 1.2 (P = .04), 1.4 (P = .03), and 1.8 (P = .002) points, respectively. Donepezil-treated patients showed greater mean improvement compared with placebo-treated patients on the following Computerized Memory Battery Test subscales: facial recognition (P = .007 in the intent-to-treat population and P = .04 in the fully evaluable population), first and last name total acquisition (P = .02), and name-face association delayed recall (P = .04). Donepezil was safe and well tolerated in this population; serious adverse events occurred in similar numbers of donepezil- and placebo-treated patients. CONCLUSION These data suggest significant treatment benefits of donepezil in early-stage Alzheimer disease, supporting the initiation of therapy early in the disease course to improve daily cognitive functioning.

[1]  B. Gordon,et al.  Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.

[2]  D. Geldmacher,et al.  Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease , 2003, Journal of the American Geriatrics Society.

[3]  T. Crook,et al.  A Computerized Battery for Assessment of Everyday Memory , 1992 .

[4]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[5]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[6]  T. Crook,et al.  Aging and everyday memory: A cross-cultural study. , 1992 .

[7]  R. Petersen,et al.  Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.

[8]  H. Mayberg,et al.  Reliability, validity, and clinical correlates of apathy in Parkinson's disease. , 1992, The Journal of neuropsychiatry and clinical neurosciences.

[9]  A. Akaike,et al.  Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical Neurons , 2003, Journal of Pharmacology and Experimental Therapeutics.

[10]  G. Hu,et al.  Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex , 1999, Neuroscience Letters.

[11]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[12]  A. Riela,et al.  Pediatric Cerebrovascular Disorders , 1988 .

[13]  Xin Yu,et al.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.

[14]  R. Katzman.,et al.  Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.

[15]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[16]  A. Kubota,et al.  Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. , 2003, European journal of pharmacology.

[17]  D. Knopman,et al.  Patterns of Care in the Early Stages of Alzheimer's Disease: Impediments to Timely Diagnosis , 2000, Journal of the American Geriatrics Society.

[18]  H.-J. Möller,et al.  The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1 , 1999, Dementia and Geriatric Cognitive Disorders.

[19]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[20]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[21]  S. Wisniewski,et al.  Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[22]  Rachelle S. Doody,et al.  DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE , 1998 .

[23]  T. Naidich,et al.  Complications of mastoiditis with special emphasis on venous sinus thrombosis. , 1982, The Journal of pediatrics.

[24]  D. Bennett,et al.  Predictors of behavioral disturbance in Alzheimer's disease. , 1991, Journal of gerontology.

[25]  D. Galasko An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour , 1998 .

[26]  B. Winblad,et al.  Mild cognitive impairment--an early stage of Alzheimer's disease? , 1998, Journal of neural transmission. Supplementum.